Pearl’s Mission is to Develop Differentiated
Therapeutics for Prevalent Respiratory Conditions
Therapeutic Area:
Respiratory
Location:
Redwood City, CA
  • Founded in 2006, Pearl Therapeutics develops inhaled fixed-dose combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
  • Pearl’s products are based on the simple and widely prescribed metered-dose inhaler (MDI) dosage form that improve on the consistency, stability, safety and efficacy of existing respiratory therapeutics. Pearl’s proprietary co-suspension formulation technology for use with MDIs enables efficient targeting and distribution of drugs to the lungs.
  • At the time of Vatera Healthcare Partners’ investment, Pearl’s lead combination new drug candidate, PT003, was a fixed-dose combination bronchodilator, composed of the long-acting muscarinic antagonist (LAMA), glycopyrronium and the long-acting ß-2 agonist (LABA), formoterol fumarate, the only LAMA/LABA combination product in late-stage development in a MDI format. In April 2016, the U.S. Food and Drug Administration approved PT003, brand name Bevespi Aerosphere, for the treatment of COPD.
  • In addition to PT003, Pearl is currently in Phase III clinical testing of PT010, a triple-drug combination of the LAMA glycopyrronium, the LABA formoterol fumarate and an inhaled corticosteroid, budesonide.
  • COPD is the third leading cause of death in the U.S.; total deaths from COPD are projected to increase by more than 30% in the next 10 years, globally.
  • More than 12 million people in the U.S. have a diagnosis of COPD and an additional 12 million likely have the disease, but remain undiagnosed.
  • Bronchodilator medications are central to symptom management in COPD. Combining bronchodilators of different pharmacological classes has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. Pearl’s technology allows for the successful combination of such drugs.
  • Vatera Healthcare Partners invested in Pearl in 2010 alongside 5AM Ventures, Clarus Ventures and New Leaf Ventures.
  • In June 2013, AstraZeneca announced the acquisition of Pearl for up to $1.15 billion to strengthen its respiratory products portfolio.